Author:
Yuan Juhua,Abdurahman Abdusami,Cui Ning,Hao Tengteng,Zou Jianhua,Liu Liren,Wu Yu
Abstract
Objective: Nowadays, primary liver carcinoma (PLC) is one of the major contributors to the global cancer burden, and China has the highest morbidity and mortality rates in the world. As a well-known Chinese herbal medicine (CHM) prescription, Huatan Sanjie Granules (HSG) has been used clinically for many years to treat PLC with remarkable efficacy, but the underlying mechanism of action remains unclear.Methods: A clinical cohort study was conducted to observe the overall survival of PLC patients with vs. without oral administration of HSG. Meanwhile, the BATMAN-TCM database was used to retrieve the potential active ingredients in the six herbs of HSG and their corresponding drug targets. PLC–related targets were then screened through the Gene Expression Omnibus (GEO) database. The protein–protein interaction (PPI) network of targets of HSG against PLC was constructed using Cytoscape software. The cell function assays were further carried out for verification.Results: The results of the cohort study showed that the median survival time of PLC patients exposed to HSG was 269 days, which was 23 days longer than that of the control group (HR, 0.62; 95% CI, 0.38–0.99; p = 0.047). In particular, the median survival time of Barcelona Clinic Liver Cancer stage C patients was 411 days in the exposure group, which was 137 days longer than that in the control group (HR, 0.59; 95% CI, 0.35–0.96; p = 0.036). Meanwhile, the enrichment analysis result for the obtained PPI network consisting of 362 potential core therapeutic targets suggest that HSG may inhibit the growth of liver cancer (LC) cells by blocking the PI3K-Akt/MAPK signaling pathways. Furthermore, the above prediction results were verified by a series of in vitro assays. Specifically, we found that the expressions TP53 and YWHA2, the targets of the hepatitis B virus signaling pathway, were significantly affected by HSG.Conclusion: HSG shows promising therapeutic efficacy in the adjuvant treatment of PLC.
Subject
Pharmacology (medical),Pharmacology
Reference34 articles.
1. Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines;Ayuso;Eur. J. radiology,2018
2. Hepatobiliary cancers, version 2.2021, NCCN linical practice guidelines in Oncology;Benson;J. Natl. Compr. Cancer Netw. JNCCN,2021
3. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis;Brentnall;BMC cell Biol.,2013
4. 14-3-3 proteins: A number of functions for a numbered protein;Bridges;Science's STKE signal Transduct. Knowl. Environ.,2005
5. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma;Bruix;Gastroenterology,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献